Founded in January 2025, Ovo Labs is a biotech company that has emerged from the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen (Germany). The company develops novel therapeutics to improve the quality of human eggs. The active compounds are designed to help women remain fertile for longer and increase their chances of a successful pregnancy and in vitro fertilization (IVF). The launch of Ovo Labs gives new impetus to the fertility industry, an area in which technological innovation is becoming increasingly important.
The novel active compounds developed by the spin-off have the potential to increase the reproductive longevity of egg cells. The underlying technologies are based on the research results of Max Planck Director, Ovo Labs co-founder and MBExC member Melina Schuh and were transferred to the start-up through an exclusive license agreement with the technology transfer organization Max Planck Innovation GmbH. The company has now raised 4 million pounds in a seed financing round to advance the development of the active substance towards clinical trials.
The team behind Ovo Labs (from left)- Dr. Agata Zielinska, Prof. Dr. Melina Schuh, and Dr. Oleksandr Yagensky. © Irene Böttcher-Gajewski _ Max Planck Institute for Multidisciplinary Sciences
